Synchronization of ovarian stimulation with follicle wave emergence in patients undergoing in vitro fertilization with a prior suboptimal response: a randomized, controlled trial

被引:12
作者
Baerwald, Angela [1 ]
Anderson, Paula [2 ]
Yuzpe, Albert [2 ]
Case, Allison [1 ]
Fluker, Margo [2 ]
机构
[1] Univ Saskatchewan, Royal Univ Hosp, Dept Obstet Gynecol & Reprod Sci, Saskatoon, SK S7N 0W8, Canada
[2] Genesis Fertil Ctr, Vancouver, BC, Canada
关键词
Suboptimal response; poor responder; ovarian stimulation; follicle wave; synchronization; NORMAL MENSTRUAL-CYCLE; ESTROUS-CYCLE; HORMONE; DYNAMICS; WOMEN; SUPEROVULATION; OVULATION; EMBRYO; PHASE; MODEL;
D O I
10.1016/j.fertnstert.2012.06.051
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To test the hypothesis that synchronizing initiation of ovarian stimulation with follicle wave emergence would optimize IVF/intracytoplasmic sperm injection (ICSI) outcomes in patients with a prior suboptimal response. Design: Prospective, randomized, controlled trial. Setting: Academic and private reproductive endocrinology and infertility centers. Patient(s): Eighty women <= 43 years of age with a history of a suboptimal response. Intervention(s): Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 1 (n = 39) or day 4 (n = 41). Main Outcome Measure(s): Numbers of clinical and biochemical pregnancies, follicles >= 10 and >= 15 mm, oocytes collected, fertilized oocytes, cleavage stage embryos, and blastocysts; serum E-2 concentrations. Outcomes were compared between treatment groups. Result(s): The numbers of follicles that developed to >= 10 and >= 15 mm and serum E-2 were greater when recombinant FSH was initiated on day 1 (5.4, 4.3, 5,827.2 pmol/L) versus day 4 (3.6, 2.5, 4,230.1 pmol/L). The numbers of collected, metaphase II, and fertilized oocytes; cleavage stage embryos; and blastocysts were not different between groups. When we evaluated only those cycles that proceeded to oocyte pick-up, a lower implantation rate (16.1%, 56.0%), biochemical pregnancy rate (PR) (16.1%, 48.0%), and clinical PR (12.9% vs. 36.0%) were detected in the day 1 group versus day 4 group. Conclusion(s): Synchronizing initiation of ovarian stimulation with follicle wave emergence in patients with a prior suboptimal response resulted in an increase in the number of dominant follicles and serum E-2 concentrations; however, improvements in oocyte, embryo, or pregnancy outcomes did not occur. Clinical Trial Registration Number: NCT00439829. (Fertil Steril (R) 2012;98:881-7. (C) 2012 by American Society for Reproductive Medicine.)
引用
收藏
页码:881 / +
页数:9
相关论文
共 50 条
  • [41] The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF
    Massin, N.
    Abdennebi, I
    Porcu-Buisson, G.
    Chevalier, N.
    Descat, E.
    Pietin-Vialle, C.
    Goro, S.
    Brussieux, M.
    Pinto, M.
    Pasquier, M.
    Bry-Gauillard, H.
    HUMAN REPRODUCTION, 2023, 38 (05) : 927 - 937
  • [42] Rescue In Vitro Maturation in Polycystic Ovarian Syndrome Patients Undergoing In Vitro Fertilization Treatment who Overrespond or Underrespond to Ovarian Stimulation: Is It A Viable Option? A Case Series Study
    Fatum, Muhammad
    Bergeron, Marie-Eve
    Ross, Caroline
    Ding, Anni
    Bhevan, Ayesha
    Turner, Karen
    Child, Tim
    INTERNATIONAL JOURNAL OF FERTILITY & STERILITY, 2020, 14 (02) : 137 - 142
  • [43] Comparison of luteal phase stimulation with follicular phase stimulation in poor ovarian response: a single-blinded randomized controlled trial
    Mozhgan Vahabi Dastjerdi
    Soheila Ansaripour
    Mina Ataei
    Roya Gharedaghi
    Seyedeh Melika Mostafavi Hoseini
    Arash Mohazzab
    Simin Zafardoust
    Contraception and Reproductive Medicine, 9
  • [44] Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome
    Pacchiarotti, Alessandro
    Carlomagno, Gianfranco
    Antonini, Gabriele
    Pacchiarotti, Arianna
    GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (01) : 69 - 73
  • [45] Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial
    Borm, G
    Mannaerts, B
    HUMAN REPRODUCTION, 2000, 15 (07) : 1490 - 1498
  • [46] Methylprednisolone for prevention of ovarian hyperstimulation syndrome in patients with polycystic ovarian syndrome undergoing in-vitro fertilisation: a randomised controlled trial
    Yeganeh, Ladan Mohammadi
    Moini, Ashraf
    Shiva, Marzieh
    Mirghavam, Naimeh
    Lankarani, Narges Bagheri
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 38 (02) : 241 - 246
  • [47] Saliva cortisol levels and subjective stress are not associated with number of oocytes after controlled ovarian hyperstimulation in patients undergoing in vitro fertilization
    Nouri, Kazem
    Litschauer, Brigitte
    Huber, Johannes C.
    Buerkle, Bernd
    Tiringer, Denise
    Tempfer, Clemens B.
    FERTILITY AND STERILITY, 2011, 96 (01) : 69 - 72
  • [48] Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization:: a randomized controlled trial
    Tazegul, Aybike
    Gorkemli, Huseyin
    Ozdemir, Suna
    Aktan, T. Murad
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2008, 278 (05) : 467 - 472
  • [49] Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol
    Schoolcraft, W
    Schlenker, T
    Gee, M
    Stevens, J
    Wagley, L
    FERTILITY AND STERILITY, 1997, 67 (01) : 93 - 97
  • [50] The role of Erzhi Tiangui formula in expected poor ovarian responders undergoing in vitro fertilization-embryo transfer: A multicenter, randomized, double-blind, placebo-controlled trial
    Han, Qiao-Song
    Zhou, Yue
    Song, Jing-Yan
    Chen, Wen
    Sun, Zhen-Gao
    MEDICINE, 2023, 102 (27) : E34088